Apnimed Prices $150M IPO on Nasdaq as FDA Clock Ticks Toward February 2027 Decision on Sleep Apnea Pill Oxnimbi

Apnimed is moving to raise $150 million on Nasdaq this week — ticker APMD — with a February 28, 2027 FDA decision date on its oral obstructive sleep apnea drug already on the calendar.

The Cambridge-based company set terms the week of July 22, 2026, planning to sell 10 million shares at $14 to $16 apiece, according to Renaissance Capital. At the midpoint of that range, the fully diluted market value would be $665 million. A July 27, 2026 SEC amendment confirmed net proceeds of $134.6 million from the base offering, rising to $155.5 million if underwriters — BofA Securities, Evercore ISI, and Cantor Fitzgerald — fully exercise their option to purchase an additional 1.5 million shares.

The drug at the center of the raise is AD109, branded Oxnimbi: a fixed-dose combination of aroxybutynin 2.3 mg and atomoxetine 75 mg, described in an Apnimed press release as a novel anti-muscarinic paired with a selective norepinephrine reuptake inhibitor. The NDA was submitted in April 2026. The FDA accepted it for review on July 14, 2026, per the company's official announcement, setting the PDUFA target action date of February 28, 2027.

The Phase III dataset behind the filing is the main argument for the valuation. Two registrational trials — SynAIRgy and LunAIRo — met their primary endpoints: mean apnea-hypopnea index reductions of 55.6% and 46.8% versus placebo, respectively, under the on-treatment estimand (p<0.0001 in both), per allsci.com's coverage of the company's disclosures. The program enrolled 1,300 patients across multiple Phase 3 trials.

Apnimed plans to spend approximately $228 million in total — covering both the regulatory finish line and a commercial launch — with the $134 million in anticipated net IPO proceeds folded into that figure, according to Before It's News citing the prospectus. The company is pre-revenue on Oxnimbi; Apnimed reported $120 million in revenue for the 12 months ended March 31, 2026, though the source of that revenue is not detailed in available filings. Japan's Shionogi is identified as the principal stockholder.

The competitive backdrop matters here. OSA affects 80 million adults in the US, with more than 20 million living with moderate-to-severe symptoms, per Fierce Biotech. The only FDA-approved pharmacological option currently on the market is Eli Lilly's Zepbound, cleared in December 2024 — but Zepbound's approval is limited to adults with obesity. Oxnimbi, if approved, would not carry that restriction, which is the strategic opening Apnimed is building toward.

Apnimed was founded in 2017. No verbatim executive quotes were available in publicly accessible prospectus excerpts at the time of publication.

With pricing expected during the week of July 27, 2026 and the PDUFA date set for February 28, 2027, the next concrete milestone is FDA approval or rejection — roughly seven months out.